Natera, Inc.
Natera is a diagnostics company specializing in cell-free DNA (cfDNA) testing and bioinformatics technology. The company leverages proprietary molecular assays and statistical algorithms to provide high-accuracy genetic testing across oncology, women’s health, and organ health. Its core value proposition is transforming disease management through non-invasive, personalized diagnostics that inform earlier and more targeted clinical interventions.
Financials
Based on Q1 2026 filing
Revenue
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Women’s Health
primaryProvides a suite of prenatal and reproductive health tests, including non-invasive prenatal testing (NIPT) and carrier screening. These products assess fetal genetic abnormalities and hereditary risks for inherited conditions.
Panorama, Horizon, Fetal RhD NIPT, Fetal Focus, Vistara, Anora, Empower
Obstetricians, Gynecologists, Maternal-fetal medicine specialists, IVF physicians
Oncology
majorFocuses on molecular residual disease (MRD) assessment and recurrence monitoring for solid tumors and blood cancers. These tests are designed to detect traces of cancer earlier than standard imaging to optimize therapy decisions.
Signatera, Latitude, Altera, Empower
Oncologists, Biopharmaceutical companies, Cancer researchers, Integrated health systems
Organ Health
moderateDevelops tests to monitor organ transplant rejection and assess genetic risks for kidney disease. These tests measure donor-derived cell-free DNA to identify early signals of active rejection in kidney, heart, and lung transplants.
Prospera Kidney, Prospera Heart, Prospera Lung, Renasight
Transplant centers, Nephrologists, Health systems
Cloud & Software Services
minorOffers a cloud-based platform that enables global laboratory partners to run molecular workflows locally while accessing Natera's proprietary bioinformatics algorithms.
Constellation, NateraCore
International clinical laboratories, Distribution partners
Segment Financials
Asia Pacific and Other — Total revenues
View metricEurope, Middle East, India, Africa — Total revenues
View metricEurope Middle East India And Africa — Revenue
View metricOncology — Revenue recognized
View metricTest Revenue — Increased revenue
View metricBusiness Overview
Competitive Position
Natera is a market leader in the U.S. NIPT space by volume and a pioneer in personalized tumor-informed MRD testing. The company maintains a strong intellectual property portfolio and extensive peer-reviewed clinical evidence to support its market position.
Geographies
United States, Global
Customer Segments
Healthcare Providers, Pharmaceutical Companies, Clinical Laboratories, Payers
Upstream Dependencies
Next-generation sequencing (NGS) platform providers, Reagent and laboratory equipment manufacturers, Cloud infrastructure providers
Downstream Customers
Physicians and specialty clinics, Hospitals and health systems, Biopharmaceutical companies, Third-party payers (Insurance and Medicare)
Competitors & Partners
Competitors
Quest Diagnostics
DGX
Competitor in NIPT, carrier screening, and oncology
Illumina
ILMN
Competitor in NIPT through its subsidiary Verinata
Labcorp Holdings
LH
Competitor in NIPT and carrier screening
Guardant Health
GH
Competitor in oncology liquid biopsy and MRD testing
Tempus AI, Inc.
TEM
Competitor in oncology diagnostics and genomic profiling
CareDx
CDNA
Primary competitor in the organ health and transplant rejection space
Myriad Genetics
MYGN
Competitor in women's health and hereditary cancer screening
Partners
UnitedHealth Group
UNH
Commercial health insurer providing coverage for NIPT and other tests
CVS Health
CVS
Commercial health insurer providing coverage for NIPT
Humana
HUM
Commercial health insurer providing coverage for NIPT
Cigna
CI
Commercial health insurer providing coverage for NIPT
Elevance Health
ELV
Commercial health insurer providing coverage for NIPT
National Cancer Institute
Research collaborator for oncology data generation
Subsidiaries
Foresight Diagnostics
Cancer diagnostics company acquired to enhance MRD testing and phased variant technology
Natera, Inc. FAQ
Common questions about Natera, Inc.
Natera is a diagnostics company specializing in cell-free DNA (cfDNA) testing and bioinformatics technology. The company leverages proprietary molecular assays and statistical algorithms to provide high-accuracy genetic testing across oncology, women’s health, and organ health. Its core value proposition is transforming disease management through non-invasive, personalized diagnostics that inform earlier and more targeted clinical interventions.
Natera, Inc. (NTRA) has a market capitalization of $27.6B and trades on NASDAQ.
Natera, Inc. generated $2.5B in trailing twelve-month revenue with a net loss of $340.5M, representing a net margin of -13.6%, with free cash flow of $104.5M. These figures are based on the Q1 2026 filing.
Natera, Inc.'s key competitors include Quest Diagnostics, Illumina, Labcorp, and others. These companies compete in similar markets and product categories.
Natera, Inc. has approximately 3,293 employees.